Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of -1.590–1.590 for the period, compared to the consensus earnings per share estimate of -1.590. The company issued revenue guidance of $350.0 million-$350.0 million, compared to the consensus revenue estimate of $349.4 million.

Fulgent Genetics Price Performance

FLGT opened at $15.19 on Friday. The company has a 50 day simple moving average of $16.31 and a two-hundred day simple moving average of $22.81. The firm has a market cap of $451.86 million, a P/E ratio of -7.75 and a beta of 0.89. Fulgent Genetics has a 1-year low of $13.46 and a 1-year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.14. The company had revenue of $83.34 million for the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Equities analysts anticipate that Fulgent Genetics will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

FLGT has been the subject of a number of recent analyst reports. Wall Street Zen lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Finally, Zacks Research lowered shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $32.00.

Hedge Funds Weigh In On Fulgent Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FLGT. Kestra Advisory Services LLC bought a new stake in Fulgent Genetics in the 4th quarter worth approximately $35,000. Raymond James Financial Inc. bought a new position in shares of Fulgent Genetics during the 2nd quarter valued at approximately $49,000. Quantbot Technologies LP purchased a new position in shares of Fulgent Genetics in the third quarter valued at $61,000. Los Angeles Capital Management LLC purchased a new position in shares of Fulgent Genetics in the fourth quarter valued at $218,000. Finally, Advisors Asset Management Inc. increased its position in Fulgent Genetics by 2,205.7% in the fourth quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock worth $223,000 after purchasing an additional 8,117 shares during the last quarter. 48.06% of the stock is owned by institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.